 |
|
Placebo Effect in Posttraumatic Stress Disorders
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: The study by Dr Brady and colleagues1 of sertraline treatment of posttraumatic stress disorder (PTSD) is a welcome addition to the sparse literature on therapeutic options for this common condition. Moreover, their conclusion that the benefit of sertraline occurred predominantly within the first 2 to 4 weeks of treatment may have important clinical implications.
However, a closer examination of the data (Tables 3 and 4), using effect size calculations (modified Cohen d values estimated from the SDs provided), suggests an alternative explanation for the observed treatment effects. Large effect sizes were demonstrated for both sertraline and placebo groups for total Clinician Administered PTSD, Part 2 (CAPS-2) (sertraline, d = 1.45 vs placebo, d = 1.0), total Impact of Event (sertraline, d = 0.97 vs placebo, d = 0.74), and Clinical Global Impression-Severity (sertraline, d = 1.18 vs placebo, d = 0.83), as well as for CAPS-2 intrusion . . . [Full Text of this Article]
RELATED ARTICLE
Efficacy and Safety of Sertraline Treatment of Posttraumatic Stress Disorder: A Randomized Controlled Trial
Kathleen Brady, Teri Pearlstein, Gregory M. Asnis, Dewleen Baker, Barbara Rothbaum, Carolyn R. Sikes, and Gail M. Farfel
JAMA. 2000;283(14):1837-1844.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Imagery Rehearsal Therapy for Chronic Nightmares in Sexual Assault Survivors With Posttraumatic Stress Disorder: A Randomized Controlled Trial
Krakow et al.
JAMA 2001;286:537-545.
ABSTRACT
| FULL TEXT
|
